UY29862A1 - Sal de dihidrógeno fosfato de un antagonista del receptor de prostaglandina d2 - Google Patents
Sal de dihidrógeno fosfato de un antagonista del receptor de prostaglandina d2Info
- Publication number
- UY29862A1 UY29862A1 UY29862A UY29862A UY29862A1 UY 29862 A1 UY29862 A1 UY 29862A1 UY 29862 A UY29862 A UY 29862A UY 29862 A UY29862 A UY 29862A UY 29862 A1 UY29862 A1 UY 29862A1
- Authority
- UY
- Uruguay
- Prior art keywords
- antagonist
- prostaglandina
- receptor antagonist
- phenyl
- phosphate dihydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Sal de dihidrogeno fosfato del ácido 2-(3-(6-(2-(2,4-dicloro-fenil)-etilamino)-2-metoxi-pirimidin-4-il)-fenil)-2-metil-propiónico de Fómula (III), una composición farmacéutica que comprende una cantidad farmacéuticamente eficaz del compuesto de Fórmula (III), y un vehículo farmacéuticamente aceptable; y un método de tratar a un paciente que padece de un trastorno mediado por PGD2. También se reivindican composiciones de este compuesto con un antihistaminico, un antagonista de leucotrieno, un antagonista beta, un inhibidor de PDEA4, un antagonista de TP, y un antagonista de CrTh2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72629005P | 2005-10-13 | 2005-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY29862A1 true UY29862A1 (es) | 2007-05-31 |
Family
ID=37963090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY29862A UY29862A1 (es) | 2005-10-13 | 2006-10-13 | Sal de dihidrógeno fosfato de un antagonista del receptor de prostaglandina d2 |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US7642249B2 (es) |
| EP (1) | EP1948620B1 (es) |
| JP (1) | JP2009511591A (es) |
| KR (1) | KR101365480B1 (es) |
| CN (1) | CN101287714B (es) |
| AR (1) | AR058085A1 (es) |
| AU (1) | AU2006304187B2 (es) |
| BR (1) | BRPI0617311A2 (es) |
| CA (1) | CA2625563C (es) |
| CR (1) | CR9870A (es) |
| DK (1) | DK1948620T3 (es) |
| DO (2) | DOP2006000223A (es) |
| EC (1) | ECSP088362A (es) |
| ES (1) | ES2409833T3 (es) |
| GT (1) | GT200600457A (es) |
| HN (1) | HN2008000603A (es) |
| HR (1) | HRP20130341T1 (es) |
| IL (1) | IL190673A (es) |
| MA (1) | MA30005B1 (es) |
| MY (1) | MY145648A (es) |
| NI (1) | NI200800116A (es) |
| NO (1) | NO20082072L (es) |
| NZ (1) | NZ567433A (es) |
| PE (1) | PE20070791A1 (es) |
| PL (1) | PL1948620T3 (es) |
| PT (1) | PT1948620E (es) |
| RS (1) | RS52799B (es) |
| RU (1) | RU2419614C2 (es) |
| SI (1) | SI1948620T1 (es) |
| TN (1) | TNSN08131A1 (es) |
| TW (1) | TW200728288A (es) |
| UA (1) | UA93062C2 (es) |
| UY (1) | UY29862A1 (es) |
| WO (1) | WO2007047378A2 (es) |
| ZA (1) | ZA200802586B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500284A (es) * | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| DOP2007000068A (es) * | 2006-04-12 | 2007-10-31 | Sanofi Aventis Us Llc | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 |
| BRPI0712332A2 (pt) * | 2006-06-09 | 2012-12-18 | Icos Corp | composto e derivados farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, método de antagonização de um receptor dp-2, e, uso de um composto |
| ATE531699T1 (de) * | 2007-06-29 | 2011-11-15 | Sanofi Sa | Verfahren zur herstellung von 2-(3-ä6-ä2-(2,4- |
| AU2009210446C1 (en) | 2008-02-01 | 2013-01-10 | Brickell Biotech, Inc. | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors |
| US8497381B2 (en) | 2008-02-25 | 2013-07-30 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
| GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
| US8524748B2 (en) | 2008-10-08 | 2013-09-03 | Panmira Pharmaceuticals, Llc | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors |
| US20100112606A1 (en) * | 2008-10-17 | 2010-05-06 | Michael Armstrong | Measurement and analysis of leukotrienes |
| TW201034675A (en) * | 2008-12-18 | 2010-10-01 | Sanofi Aventis | Method for treating macular degeneration |
| SG178109A1 (en) | 2009-07-31 | 2012-03-29 | Panmira Pharmaceuticals Llc | Ophthalmic pharmaceutical compositions of dp2 receptor antagonists |
| JP2013501052A (ja) | 2009-08-05 | 2013-01-10 | パンミラ ファーマシューティカルズ，エルエルシー． | Ｄｐ２アンタゴニストおよびその用途 |
| US20130123365A1 (en) | 2010-07-08 | 2013-05-16 | Ramot At Tel-Aviv University Ltd. | Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions |
| WO2012044561A2 (en) * | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | 2-alkoxy pyrimidine pde10 inhibitors |
| WO2014066568A1 (en) | 2012-10-24 | 2014-05-01 | Winthrop-University Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
| US20180021302A1 (en) | 2015-02-13 | 2018-01-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
| SI3302448T1 (sl) | 2015-06-04 | 2024-03-29 | Aurigene Oncology Limited | Substituirani heterociklični derivati kot inhibitorji cdk |
| KR20200109293A (ko) | 2017-09-13 | 2020-09-22 | 프로제너티, 인크. | 자간전증 바이오마커 및 관련된 시스템 및 방법 |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711888A (en) * | 1985-07-24 | 1987-12-08 | Pfizer Inc. | Hydroxy and alkoxy pyrimidines |
| WO2003049739A1 (en) * | 2001-12-07 | 2003-06-19 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as gsk-3 inhibitors |
| CN1849308A (zh) * | 2003-07-09 | 2006-10-18 | 弗·哈夫曼-拉罗切有限公司 | 硫代苯基氨基咪唑啉 |
| GT200500284A (es) * | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
-
2006
- 2006-10-11 GT GT200600457A patent/GT200600457A/es unknown
- 2006-10-12 NZ NZ567433A patent/NZ567433A/en not_active IP Right Cessation
- 2006-10-12 JP JP2008535672A patent/JP2009511591A/ja not_active Abandoned
- 2006-10-12 PT PT68258367T patent/PT1948620E/pt unknown
- 2006-10-12 CN CN2006800378860A patent/CN101287714B/zh not_active Expired - Fee Related
- 2006-10-12 PE PE2006001242A patent/PE20070791A1/es not_active Application Discontinuation
- 2006-10-12 BR BRPI0617311-0A patent/BRPI0617311A2/pt not_active IP Right Cessation
- 2006-10-12 RS RS20130225A patent/RS52799B/sr unknown
- 2006-10-12 KR KR1020087008805A patent/KR101365480B1/ko not_active Expired - Fee Related
- 2006-10-12 MY MYPI20081085A patent/MY145648A/en unknown
- 2006-10-12 RU RU2008118491/04A patent/RU2419614C2/ru not_active IP Right Cessation
- 2006-10-12 AU AU2006304187A patent/AU2006304187B2/en not_active Ceased
- 2006-10-12 PL PL06825836T patent/PL1948620T3/pl unknown
- 2006-10-12 DK DK06825836.7T patent/DK1948620T3/da active
- 2006-10-12 EP EP06825836A patent/EP1948620B1/en active Active
- 2006-10-12 AR ARP060104475A patent/AR058085A1/es not_active Application Discontinuation
- 2006-10-12 WO PCT/US2006/039901 patent/WO2007047378A2/en not_active Ceased
- 2006-10-12 CA CA2625563A patent/CA2625563C/en not_active Expired - Fee Related
- 2006-10-12 SI SI200631572T patent/SI1948620T1/sl unknown
- 2006-10-12 UA UAA200806196A patent/UA93062C2/ru unknown
- 2006-10-12 ES ES06825836T patent/ES2409833T3/es active Active
- 2006-10-12 HR HRP20130341TT patent/HRP20130341T1/hr unknown
- 2006-10-13 TW TW095137635A patent/TW200728288A/zh unknown
- 2006-10-13 DO DO2006P000223A patent/DOP2006000223A/es unknown
- 2006-10-13 DO DO2006000220A patent/DOP2006000220A/es unknown
- 2006-10-13 UY UY29862A patent/UY29862A1/es unknown
-
2008
- 2008-03-19 TN TNP2008000131A patent/TNSN08131A1/en unknown
- 2008-03-20 ZA ZA200802586A patent/ZA200802586B/xx unknown
- 2008-04-07 CR CR9870A patent/CR9870A/es not_active Application Discontinuation
- 2008-04-07 IL IL190673A patent/IL190673A/en not_active IP Right Cessation
- 2008-04-10 EC EC2008008362A patent/ECSP088362A/es unknown
- 2008-04-11 US US12/101,282 patent/US7642249B2/en not_active Expired - Fee Related
- 2008-04-11 HN HN2008000603A patent/HN2008000603A/es unknown
- 2008-04-11 NI NI200800116A patent/NI200800116A/es unknown
- 2008-05-02 NO NO20082072A patent/NO20082072L/no not_active Application Discontinuation
- 2008-05-02 MA MA30890A patent/MA30005B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY29862A1 (es) | Sal de dihidrógeno fosfato de un antagonista del receptor de prostaglandina d2 | |
| PE20130239A1 (es) | Compuestos heteroaril-aril-ureas como inhibidores de la quinasa | |
| MA32014B1 (fr) | Composes condenses de pyridine, de pyrimidine et de triazine en tant qu'inhibiteurs du cycle cellulaire | |
| NO20070893L (no) | Hydantoinderivater for behandling av inflammasjonslidelser. | |
| MA30412B1 (fr) | Composés Pharmaceutiques | |
| NZ595553A (en) | VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol | |
| MX2010010525A (es) | Inhibidores de metaloproteasa de matriz basados en aril-sulfonamida. | |
| NZ592425A (en) | Isoindoline compounds for use in the treatment of cancer | |
| TNSN07325A1 (en) | Pgd2 receptor antagonists for the treatment of inflammatory diseases | |
| NO20051100L (no) | Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer | |
| UA93351C2 (uk) | Похідні фталазіну як інгібітори parp | |
| BR0316583A (pt) | Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1) | |
| TN2009000225A1 (en) | Compounds and compositions as protein kinase kinase inhibitors | |
| MA29799B1 (fr) | Administration d'inhibiteurs de dipeptidyl peptidase | |
| RU2009110442A (ru) | Конденсированные производные имидазола для лечения нарушений, опосредованных альдостеронсинтазой, и/или 11-бета-гидроксилазой, и/или ароматазой | |
| BRPI0410711B8 (pt) | ácido 4-(acetilamina)-3-[(4-clorofenil)tio]-2-metil-1h-indol-1-acético | |
| CY1108573T1 (el) | Ανταγωνιστες νρυυ5 | |
| NO20082834L (no) | 2-(fenyl eller heterosyklisk)-1H-fenantro[9,10-D]imidazoler som MPGES-1-inhibitorer | |
| DE60335869D1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
| TW200612911A (en) | Compounds for the treatment of inflammatory disorders | |
| DK0705254T3 (da) | Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer | |
| NO20080391L (no) | Pyrazolbaserte LXR modulatorer | |
| JP2011525897A (ja) | 新しい治療用作用物質 | |
| WO2007136640A3 (en) | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | |
| EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DESI | Application deemed to be withdrawn |
Effective date: 20120515 |